The incidence of prostate cancer (PCa) has dramatically increased since the introduction of prostate-specific antigen (PSA) screening in the late 1980s. Significant variations have been reported for the incidence of PCa between races and regions. For instance, Asian countries are known to have a low incidence, which is onetenth compared to the highest incidence in European countries, 1